SAGE Overview
Upcoming Projects (SAGE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SAGE)
-
Examining Sage Therapeutic's SAGE-718 in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease and its recent Phase 2 LUMINARY trial results presented at AAN
Ticker: SAGE
Executed On: Apr 28, 2022 at 04:15 PM EDT -
A discussion of zuranolone in MDD: As data continues to be released what does the CORAL study say about the drug's future?
Ticker: SAGE
Executed On: Mar 08, 2022 at 12:00 PM EST -
Discussing the potential of Zuranolone (SAGE-217) in Major Depressive Disorder before NDA expected in the 2nd Half of 2022
Ticker: SAGE
Executed On: Jan 27, 2022 at 04:00 PM EST
Expired Projects (SAGE)
-
Discussing Sage’s SAGE-718 in Alzheimer’s Disease Dementia
Ticker: SAGE
Execute By: May 31, 2022 -
Analyzing Marinus’ Ganaxolone in treating Postpartum Depression, after its Phase 2 Magnolia and Amaryllis trials data
Tickers: MRNS, SAGE
Execute By: Aug 28, 2018
Upcoming & Overdue Catalysts (SAGE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SAGE)
-
Phase 1 biomarker data of Sage Therapeutics' (SAGE) SAGE-718 in Huntington's disease due July 2019
Ticker: SAGE
Occurred on: Jul 24, 2019 -
Phase 1 MAD data of Sage Therapeutics' (SAGE) SAGE-324 in Essential tremor due July 2019
Ticker: SAGE
Occurred on: Jul 24, 2019 -
SAGE 547 May Not Go On Sale Until 2018 (Assuming FDA Approval; PDUFA Dec 19 2018)
Ticker: SAGE
Occurred on: Nov 20, 2018 -
SAGE Expects NDA Filing for SAGE 547 2nd Half of 2017
Ticker: SAGE
Occurred on: Apr 23, 2018 -
Phase 2 Top-Line Data for SAGE-217 in Postpartum Depression due H2 2017
Ticker: SAGE
Occurred on: Apr 17, 2018 -
Phase 2 Open-Label Data Evaluating SAGE-217 in Major Depressive Disorder Due H1 2017
Ticker: SAGE
Occurred on: Dec 07, 2017 -
SAGE Top-Line Phase 3 Data Evaluating SAGE-547 in Moderate and Severe Postpartum Depression due H2 2017
Ticker: SAGE
Occurred on: Nov 09, 2017 -
Phase 2 Open-Label Data Evaluating SAGE-217 in Parkinson's Disease Due H1 2017
Ticker: SAGE
Occurred on: Nov 02, 2017 -
Phase 2 Top-Line Data Evaluating SAGE-217 in Essential Tremor Due H2 2017
Ticker: SAGE
Occurred on: Nov 02, 2017 -
EMA Scientific Advice for SAGE-547 in Postpartum Depression Due H1 2017
Ticker: SAGE
Occurred on: Aug 03, 2017 -
SAGE's First NMDA Program (SAGE 718) Could Enter Clinical Trials Mid-2017
Ticker: SAGE
Occurred on: Apr 27, 2017 -
Top-line Data from Phase 2 Proof-of-Concept Trial of SAGE-217 in Parkinson's Disease
Ticker: SAGE
Occurred on: Feb 13, 2017 -
Sage Therapeutics (SAGE) Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders
Ticker: SAGE
Occurred on: Dec 19, 2016 -
SAGE Plans to Initiate Phase 2 Trials for SAGE 217 (Essential Tremors and Orphan Epilepsies) 2nd Half of 2016
Ticker: SAGE
Occurred on: Dec 13, 2016 -
Sage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression
Ticker: SAGE
Occurred on: Sep 06, 2016
Strategic Initiatives (SAGE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
